MASTER PROTOCOL OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL-GROUP STUDIES OF DUPILUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) WHO REMAIN SYMPTOMATIC DESPITE THE USE OF H1 ANTIHISTAMINE TREATMENT IN PATIENTS NAIVE TO OMALIZUMAB AND IN PATIENTS WHO ARE INTOLERANT OR INCOMPLETE RESPONDERS TO OMALIZUMAB
- Registry ID
- EFC16461
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2020-08-08
- Last update
- 2019-12-18
Conditions
- CHRONIC SPONTANEOUS URTICARIA
Related clinical trials
- A PHASE 3B LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY OF BARZOLVOLIMAB IN PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA WHO HAVE COMPLETED CDX0159-12 OR CDX0159-13 (EMBARQ-CSULTE)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS
URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT
(EMBARQ - CSU1)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU2)
- AN OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PK,
IMMUNOGENICITY, AND CLINICAL RESPONSE OF MULTIPLE DOSES OF IV AK006 IN
SUBJECTS WITH H1 ANTIHISTAMINE REFRACTORY CHRONIC SPONTANEOUS URTICARIA
COMPLETING STUDY AK006-001
- A GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, PHASE 3B STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB 25 MG B.I.D. IN COMPARISON TO PLACEBO WITH OMALIZUMAB 300 MG EVERY 4 WEEKS AS ACTIVE CONTROL OVER 52 WEEKS IN ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED BY SECOND-GENERATION H1-ANTIHISTAMINES, AND AN OPEN-LABEL 52-WEEK OPTIONAL EXTENSION TO ASSESS LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB 25
- A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL AND OPEN-LABEL EXTENSION STUDY FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT CYCLES TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN ADULT CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED THE PRECEDING REMIBRUTINIB PHASE 3 STUDIES
View on source registry